12 unknown, 4 recruiting, 2 not yet recruiting, 2 withdrawn. 11 Phase 2, 6 Phase 3, 3 Phase 4, 1 Not applicable, 1 Phase 1.
Follow pirarubicin: new trials by email Literature Review of pirarubicin trials Research Report on pirarubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pirarubicin, Nab-paclitaxel - TNBC, Triple Negative Breast Cancer | Phase 1 | Recruiting | Xijing Hospital | 30 | 2025-11-06 | 2025-11-24 |
| Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma Trilaciclib, Pirarubicin, Lobaplatin - Osteosarcoma | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-11-13 | 2024-12-03 |
| Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study doxorubicin, epirubicin, pirarubicin - Breast Cancer | Not applicable | Not yet recruiting | Chinese Academy of Medical Sciences | 500 | 2022-03-01 | 2022-03-31 |
| Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy Epirubicin or Pirarubicin, Cyclophosphamide - Triple Negative Breast Cancer | Phase 2 | Recruiting | Chinese Academy of Medical Sciences | 286 | 2020-02-01 | 2020-06-18 |
| Combination Therapy of Anthracyclines for Children With Nephroblastoma Vincristine, Oxytetracycline/ Cyclophosphamide, Liposomal doxorubicin - 0.5-14 Year Old Children With Nephroblastoma | Phase 4 | Not yet recruiting | Shengjing Hospital | 120 | 2019-06-01 | 2019-03-27 |
| Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma Apatinib Mesylate, Pirarubicin, Ifosfamide, Apatinib Mesylate, Pirarubicin, Ifosfamide - Soft Tissue Sarcoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 120 | 2019-06-01 | 2019-10-15 |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma pegylated liposomal doxorubicin, pirarubicin - Progression-free Survival, Overall Survival | Phase 2 / Phase 3 | Withdrawn | Peking University People's Hospital | 2017-11-06 | 2020-05-19 | |
| Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma pirarubicin(THP) - Intravesical Instillation | Phase 2 | Unknown | RenJi Hospital | 220 | 2017-01-01 | 2019-10-09 |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients Pirarubicin - Bladder Recurrence, Upper Tract Urothelial Carcinoma | Phase 2 | Unknown | Peking University First Hospital | 200 | 2016-11-01 | 2016-11-17 |
| Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy Pegylated Liposomal Doxorubicin, Cyclophosphamide, Taxotere - Antineoplastic Combined Chemotherapy Protocols | Phase 2 | Unknown | Jilin University | 160 | 2016-11-01 | 2017-12-29 |
| Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Doxorubicin Hydrochloride Liposome injection and cyclophosphamide, pirarubicin and cyclophosphamide - Breast Cancer | Phase 4 | Unknown | Hebei Medical University Fourth Hospital | 300 | 2016-09-01 | 2016-09-16 |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients Pirarubicin - Upper Tract Urothelial Carcinoma, Bladder Recurrence | Phase 2 | Unknown | Peking University First Hospital | 200 | 2016-08-01 | 2017-09-21 |
| Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma Pirarubicin, Oxaliplatin, Lipiodol - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Withdrawn | Guangxi Medical University | 2015-10-01 | 2019-06-04 | |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas pharmorubicin or pirarubicin - Upper Tract Urothelial Carcinoma, Bladder Recurrence | Phase 2 | Unknown | Xuesong Li | 200 | 2015-09-01 | 2015-09-11 |
| Combine TACE and RFA Versus TACE Alone for HCC With PVTT TACE, RFA, pirarubicin,mitomycin and lobaplatin - Hepatocellular Carcinoma | Phase 3 | Unknown | Ming Zhao | 240 | 2014-10-01 | 2016-04-14 |
| Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma liver resection, transarterial chemoembolization, carboplatin - Hepatocellular Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 198 | 2014-03-01 | 2016-04-28 |
| CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Unknown | Ruijin Hospital | 200 | 2012-09-01 | 2017-11-14 |
| Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer Pirarubicin, Docetaxel, Cyclophosphamide - Breast Neoplasms | Phase 3 | Completed | 307 Hospital of PLA | 104 | 2009-07-01 | 2015-11-24 |
Showing 20 of 21. Sign in to see all of them.
Breast Neoplasms (4) · Carcinoma, Hepatocellular (3) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Enteropathy-Associated T-Cell Lymphoma (1) · Immunoblastic Lymphadenopathy (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Osteosarcoma (1) · Pathologic Complete Response (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Subcutaneous panniculitis-like T-cell lymphoma (1) · Urinary Bladder Neoplasms (1) · Wilms Tumor (1)
Chinese Academy of Medical Sciences (2) · Peking University First Hospital (2) · Peking University People's Hospital (2) · Xijing Hospital (2) · 307 Hospital of PLA (1) · Guangxi Medical University (1) · Hebei Medical University Fourth Hospital (1) · Japan Adult Leukemia Study Group (1) · Jilin University (1) · Ming Zhao (1) · RenJi Hospital (1) · Ruijin Hospital (1) · Shengjing Hospital (1) · Sun Yat-sen University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
China (18) · Japan (1)
Aiping Shi, Doctor (1) · Fumihiko Hayakawa, MD (1) · Lequn Li, PhD (1) · Ming Zhao, doctor (1) · Shikai Wu (1) · Tomoki Naoe, MD (1) · Wei Guo, M.D.and Ph.D. (1)